Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

Summary

This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.

Timeline

Start

2019-01-04

Primary completion

2025-03-17

Completion

2026-12-23

Outcome

Met primary endpoint

registry analysis (superiority test); Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D+O; p <0.0001; Hazard Ratio (HR) 0.63 (95% CI 0.52 to 0.76); NCT03737643 ↗

registry analysis (superiority test); Global Non-tBRCAm: SoC vs Global Non-tBRCAm: SoC+D+O; p <0.0001; Hazard Ratio (HR) 0.49 (95% CI 0.34 to 0.69); NCT03737643 ↗

release “DUO-O Phase III trial showed treatment with a combination of Lynparza (olaparib), Imfinzi (durvalumab), chemotherapy and bevacizumab demonstrated a statistically significant and clinically meaningful improvement” astrazeneca.com ↗

release “The DUO-O trial interim progression-free survival analysis provide evidence for further improvement with olaparib and durvalumab combination versus chemotherapy and bevacizumab alone.” astrazeneca.com ↗

Publications

• Gaitskell K, Rogozinska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	—	Intravenous
Subject	Durvalumab	Monoclonal antibody	—	Intravenous
Subject	Olaparib	Small molecule	—	Oral
Background	Carboplatin	Small molecule	—	—
Background	Paclitaxel	Small molecule	—	—

Indications